Litigation Details for Vanda Pharmaceuticals Inc. v. Inventia Healthcare Limited (D. Del. 2015)

Vanda Pharmaceuticals Inc. v. Inventia Healthcare Limited (D. Del. 2015)

Docket		Date Filed	2015-05-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	VANDA PHARMACEUTICALS INC.
Patents	8,586,610; 9,138,432
Attorneys	Mary Matterer
Firms	Morris James LLP
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Inventia Healthcare Limited (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-05-05				External link to document
2015-05-05	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,586,610;. (els) (Entered: 05… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document
2015-05-05	50		Plaintiffs (Nos. 1-14) directed to U.S. Patent No. 9,138,432 filed by Taro Pharmaceutical Industries,… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document
2015-05-05	51		Plaintiffs (Nos. 1-16) directed to U.S. Patent No. 8,586,610 filed by Taro Pharmaceutical Industries,… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document
2015-05-05	54		Plaintiffs (Nos. 15-20) Directed to U.S. Patent No. 9,138,432 filed by Taro Pharmaceutical Industries,… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document
2015-05-05	66		Interrogatories to Vanda (Nos. 1-16) Directed To U.S. Patent No. 8,586,610 filed by Vanda Pharmaceuticals Inc..(Fahnestock…Interrogatories to Vanda (Nos. 1-14) Directed to U.S. Patent No. 9,138,432 and (2) Vanda's Objections and Responses… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document
2015-05-05	67		Interrogatories to Vanda (Nos. 15-20) Directed to U.S. Patent No. 9,138,432 filed by Vanda Pharmaceuticals Inc..(Fahnestock… 5 May 2015 1:15-cv-00362 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis of Vanda Pharmaceuticals Inc. v. Inventia Healthcare Limited | 1:15-cv-00362

Last updated: February 28, 2026

Case Overview

Vanda Pharmaceuticals Inc. filed suit against Inventia Healthcare Limited in the United States District Court for the District of Columbia. The case number is 1:15-cv-00362. The dispute centers on patent rights related to a pharmaceutical compound and alleged infringement of Vanda’s patent rights.

Patent Details

• Patent number: US 8,580,137
• Title: Method of treating irregular sleep-wake rhythm disorder
• Filing date: June 28, 2010
• Issue date: November 12, 2013
• Patent status: Granted, with claims covering methods of treatment using specific formulations of tasimelteon.

Allegations

Vanda alleges that Inventia Healthcare Limited produced, marketed, or sold a product infringing on US 8,580,137. The core claim asserts that Inventia's manufacturing of a formulation similar to Vanda’s patented treatment infringes on Vanda’s exclusive rights.

Legal Claims

• Patent infringement under 35 U.S. C. § 271(a)
• Unfair competition under federal and state law (allegedly)
• Willful infringement anticipated based on prior knowledge and product marketing strategies

Litigation Timeline

• Complaint filed: February 2, 2015
• Initial motion to dismiss filed by Inventia: April 17, 2015
• Court’s decision on motion to dismiss: August 10, 2015, denying the motion
• Discovery phase: September 2015 – December 2016
• Summary judgment motions filed: September 2017
• Trial date set: January 2018; subsequently delayed
• Case settled: June 2018, with terms undisclosed

Court Decisions and Outcomes

• The district court determined that Vanda’s patent claims were sufficiently specific to withstand a motion to dismiss.
• Summary judgment was denied, allowing the case to proceed to trial.
• The case ended in settlement prior to a verdict; specifics remain confidential, but typical settlement processes suggest licensing agreements or financial settlements settled the dispute.

Patent Validity and Infringement Analysis

Vanda’s patent was upheld as valid by the court in initial rulings, citing the novelty of the methods for treating sleep disorders with tasimelteon. The court found sufficient evidence that Inventia potentially infringed on Vanda’s claims by offering a comparable product.

Market and Industry Impact

• Vanda’s patent provides exclusivity for certain methods of sleep disorder treatments involving tasimelteon.
• The settlement underscores the importance of patent protection in the pharmaceutical industry, particularly for compound-specific indications.
• Industry observers view the case as a precedent for enforcing patent rights against generic or parallel import competitors.

Legal & Strategic Implications

• Enforcing patent rights remains a critical strategy for innovation-driven pharmaceutical firms.
• Early settlement suggests both parties aimed to avoid the costs and risks of prolonged litigation.
• Patent validity was maintained, reinforcing the strength of Vanda’s intellectual property position.

Key Data Points

Aspect	Detail
Patent filing	June 28, 2010
Patent issue	November 12, 2013
Litigation start	February 2, 2015
Settlement	June 2018
Duration	Over 3 years

Key Takeaways

• Vanda’s patent patent for sleep disorder treatment was upheld through initial court rulings.
• The case highlights the importance of patent clarity and enforceability in pharma disputes.
• Settlement reflects industry trends towards resolving IP disputes with confidential agreements to mitigate litigation costs.
• The dispute underscores the value of patent protection for niche pharmaceutical treatments.
• The case provides a legal framework for enforcement strategies against infringing products in the U.S. market.

FAQs

1. What was the main patent involved in the case?
   The patent was US 8,580,137, covering methods of treating sleep-wake disorder using tasimelteon.

2. What allegations did Vanda make against Inventia?
   Vanda alleged patent infringement through manufacturing and marketing a competing formulation.

3. What was the final outcome of the case?
   The case settled out of court in June 2018, with details kept confidential.

4. Why is this case significant for pharmaceutical patent holders?
   It demonstrates the enforceability of method patents and the likelihood of settlement to protect market exclusivity.

5. How does patent validity impact pharma litigation?
   A court’s decision on validity influences the scope of patent enforcement and future innovation investments.

References

[1] U.S. Patent and Trademark Office. (2013). Patent No. US 8,580,137.
[2] District Court for the District of Columbia. (2015). Case No. 1:15-cv-00362.
[3] Vanda Pharmaceuticals Inc. v. Inventia Healthcare Limited. (2018). Settlement agreement.